At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 711 enrolled
Drug / intervention
Lifitegrast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
In Brief
A Phase 3 clinical trial evaluating Lifitegrast and Placebo for Dry Eye Disease. Completed, enrolled 711 participants across 41 sites.
Detailed Summary
Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartNov 2014
Primary CompletionOct 2015
TodayJul 2026
First PostedNov 6, 2014
Enrollment StartNov 6, 2014
Primary CompletionOct 5, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.7 years ago
Interventions
Lifitegrastdrug
Lifitegrast Ophthalmic Solution 5%, BID for 84 days
Placebodrug
Placebo to match active treatment, BID for 84 days